Results 111 to 120 of about 655,557 (182)

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

HemaSphere, Volume 10, Issue 10, October 2026.
Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, Shirong Liu, Hao Sun, Xia Liu, María L. Guerrera, Andrew R. Branagan, Gottfried von Keudell, Shayna R. Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon   +18 more
wiley   +1 more source

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and Perspectives

The introduction of Bruton tyrosine kinase inhibitors (BTKis) has significantly improved prognosis in the treatment of MCL. BTK inhibitors have demonstrated strong activity in the treatment of relapsed/refractory patients with mantle cell lymphoma (MCL),
Tadeusz Robak, Paweł Robak, Anna Wolska-Washer   +2 more
core   +1 more source

''From Molecular Resistance to Tumor Evolution: Insights in BTK Inhibitors, Tumor Microenvironment and Genetic Variants.''

reservedBruton’s tyrosine kinase (BTK) prevails as a key mediator in the elaborate system of immune signaling, with its essential role in maintaining homeostasis of the B lymphocyte compartment.
RUSTEMI, BRISEJDA
core  

Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors

Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown.
Jahan Rahman, Samantha Sekeres, Ya-Wen Lu, Anthony R. Mato, Justin Taylor, Meghan C. Thompson, Allison Cool, Xiaoli Mi, Jennifer Elechko, Hugo Bousquet, Tim Kong, Nell Narasappa, Jordan Ye, Emel Ficici, May Tan, Stefan Gajewski, Sarah Whelan, Christopher B. Phelps, Alvaro Alencar, Gwenn M. Hansen, Quinlan Sievers, Eduardo Bravo, James N. Iuliano, Maxim I. Maron, Omar Abdel-Wahab, Shruti Bhatt, Mark D. Ewalt, Mateo Sanchez Garcia De Los Rios, Yuhan Wang, Erica N. Lamkin, Prioty Islam, Lizbeth Mendoza Navarrete, Nivetha Brathaban, Lindsey Roeker, Mark A. Noviski, Ratul Mukerji, Hao Lu, Ryan Q. Notti   +37 more
core   +1 more source

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

The Journal of Clinical Investigation
Bruton tyrosine kinase (BTK) inhibitor therapy induces peripheral blood lymphocytosis in chronic lymphocytic leukemia (CLL), which lasts for several months.
Laura Ondrisova, Vaclav Seda, Krystof Hlavac, Petra Pavelkova, Eva Hoferkova, Giorgia Chiodin, Lenka Kostalova, Gabriela Mladonicka Pavlasova, Daniel Filip, Josef Vecera, Pedro Faria Zeni, Jan Oppelt, Zuzana Kahounova, Rachel Vichova, Karel Soucek, Anna Panovska, Karla Plevova, Sarka Pospisilova, Martin Simkovic, Filip Vrbacky, Daniel Lysak, Stacey M. Fernandes, Matthew S. Davids, Alba Maiques-Diaz, Stella Charalampopoulou, Jose I. Martin-Subero, Jennifer R. Brown, Michael Doubek, Francesco Forconi, Jiri Mayer, Marek Mraz   +30 more
doaj   +1 more source

Continuous or fixed-duration BTK inhibitor treatment for WM. [PDF]

Blood Adv
Yi S, Qiu L.
europepmc   +1 more source

BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance. [PDF]

Nat Commun
Hwang SY, Huang X, Nikolli H, Yoval-Sánchez B, Yang S, Heo J, Martin P, Gribbin C, Jain P, Wang M, Sehgal L, Baiocchi RA, Hwang I, DiLiberto M, Galkin A, Kwak H, Alinari L, Chen-Kiang S, Zheng H, Paik J.   +19 more
europepmc   +1 more source

TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]

Blood Adv
Niemann CU.
europepmc   +1 more source

Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma. [PDF]

Hematol Oncol
Jiang S, Liu Y, Wei R, Zhang W, Bao L, Jin J, Lv F, Liu C, Liu X, Sun H, Wang J, Tao R, Cao J, Zhou X, Zhang Q.   +14 more
europepmc   +1 more source

New Means and Challenges in the Targeting of BTK

Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders.
Sondhi, Anya K., Abdel-Wahab, Omar, Nawaratne, Vindhya, Taylor, Justin   +3 more
core   +1 more source